References
- Howlader N, Noone A, Krapcho M, . SEER Cancer Statistics Review, 1975-2008. [Based on November 2010 SEER data submission, posted to the SEER website 2011.] Bethesda, MD: National Cancer Institute. Available from: http://seer.cancer.gov/csr/1975_2008/
- Palumbo A, Bringhen S, Ludwig H, . Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood 2011;118:4519–4529.
- Dimopoulos M, Spencer A, Attal M, . Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123–2132.
- Weber DM, Chen C, Niesvizky R, . Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357:2133–2142.
- Dimopoulos MA, Hussein M, Swern AS, . Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma. Leukemia 2011;25:1620–1626.
- Durie BG, Harousseau JL, Miguel JS, . International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467–1473.
- Lonial S, Knight RD, Dimopoulos M, . Effect of Len/Dex in MM in different age groups. Haematologica 2007;92(Suppl. 2): Abstract PO–663.
- Quach H, Fernyhough L, Henderson R, . Lower-dose lenalidomide and dexamethasone reduces toxicity without compromising efficacy in patients with relapsed/refracory myeloma, who are aged ≥ 65 years or have renal impairment: planned interim results of a prospective multicentre phase II trial. Blood 2010;116(Suppl. 1): Abstract 1961.
- Rajkumar SV, Jacobus S, Callander NS, . Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010;11:29–37.
- Zonder JA, Crowley J, Hussein MA, . Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). Blood 2010;116:5838–5841.